Arête Discoveries is a biotech research discovery firm formed to develop treatments to stop the progression of autoimmune diseases. Our research focuses on the innate immune system and the epigenetic impact on tissues throughout the human body. The first target of Arête's research is amyotrophic lateral sclerosis (ALS). The one commonality in all neurodegenerative disease is inflammation. Our candidates, ART201a and ART201b (ART201), work in multiple mechanisms of action to reduce, even eliminate, harmful inflammation, prevent pathogenesis and stimulate stromal precursor cells, providing tissue repair and amelioration of disease. We will use nanotechnology to deliver ART201 directly to diseased tissue, greatly reducing the possibility of adverse reactions, side effects or toxicity.
What if science missed a key piece of evidence?
What if a fresh perspective was brought to the autoimmune space that was not encumbered by any preconceived understandings, or centuries old medical dogma?
That "what if" is now!
Arête Discoveries has taken an entirely novel approach to both understanding autoimmune disease, and uncovering heretofore unknown biological interactions. We believe we have found the trigger, the precursor, that initiates the pathogenesis of autoimmunity. We define autoimmunity as any condition or disease that is not viral, bacterial or traumatic injury. Our discoveries of mutations at the precursor, stem cell and RNA level, combined with cutting edge anatomical discoveries and understandings, have allowed us to see further, faster than any company or group of researchers has done before.
Arête Discoveries is currently seeking support from family foundations, private individuals, as well as non-diluting collaboration with forward thinking pharmaceutical companies and bio-pharma discovery firms.